Discussion on Follow-on Biosimilars
On July 11, 2009 NATF held a open discussion on the Congressional and Senatorial Bills related to Follow-on Biosimilars. NATF’s Official Statement on issues of patient safety was presented and discussed. The presentations and related material is available below.
 |
Introduction, Video Samuel Z. Goldhaber, MD |
 |
Introductory Remarks Video Jawed Fareed, PhD |
 |
Update on Heparin Contaminants and Quality Issues Surrounding Unfractionated Heparin (PDF)
John Fanikos, RPh, MBA |
 |
Current Issues and Statements Surrounding Biosimilars and Follow-on Biologics (PDF) Video Andrew Whelton, MD |
 |
Panel Discussion Video #1 | ||
 |
Summary of United States Legislation and Proposed Bills (PDF) Video Craig M. Jackson , PhD |
 |
European Perspective on Biosimilars and Follow-on Biologics (PDF) Video Wolfram Raake, DVM |
 |
NATF’s Official Position on Follow-on Biologics (PDF) Call to Action for the Protection of Patient Safety (Video) Craig M. Kessler, MD |
 |
Genzyme Corporation, Video Kay Holcombe, MS |
 |
Recommendations on Biosimilar LMWHs, Video Job Harenberg, DVM |
 |
Presentation, Video NATT: Randy Fenninger |
 |
Panel Discussion Video #2 |
Make a donation through PayPal, it's easy, safe and quick.
Follow US!
